Alonso-Alonso María L, Srivastava Girish K
María L Alonso-Alonso, Girish K Srivastava, Instituto Universitario de Obtalmobiología Aplicada (IOBA), Universidad de Valladolid, 47011 Valladolid, Spain.
World J Stem Cells. 2015 Apr 26;7(3):641-8. doi: 10.4252/wjsc.v7.i3.641.
The relevance of retinal diseases, both in society's economy and in the quality of people's life who suffer with them, has made stem cell therapy an interesting topic for research. Embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and adipose derived mesenchymal stem cells (ADMSCs) are the focus in current endeavors as a source of different retinal cells, such as photoreceptors and retinal pigment epithelial cells. The aim is to apply them for cell replacement as an option for treating retinal diseases which so far are untreatable in their advanced stage. ESCs, despite the great potential for differentiation, have the dangerous risk of teratoma formation as well as ethical issues, which must be resolved before starting a clinical trial. iPSCs, like ESCs, are able to differentiate in to several types of retinal cells. However, the process to get them for personalized cell therapy has a high cost in terms of time and money. Researchers are working to resolve this since iPSCs seem to be a realistic option for treating retinal diseases. ADMSCs have the advantage that the procedures to obtain them are easier. Despite advancements in stem cell application, there are still several challenges that need to be overcome before transferring the research results to clinical application. This paper reviews recent research achievements of the applications of these three types of stem cells as well as clinical trials currently based on them.
视网膜疾病在社会经济以及患者生活质量方面都具有重要意义,这使得干细胞疗法成为一个备受关注的研究课题。胚胎干细胞(ESCs)、诱导多能干细胞(iPSCs)和脂肪来源间充质干细胞(ADMSCs)是目前研究的重点,有望成为不同视网膜细胞(如光感受器和视网膜色素上皮细胞)的来源。其目的是将这些细胞用于细胞替代疗法,以治疗目前处于晚期仍无法治愈的视网膜疾病。尽管胚胎干细胞具有巨大的分化潜力,但存在形成畸胎瘤的风险以及伦理问题,在开展临床试验之前必须解决这些问题。诱导多能干细胞与胚胎干细胞一样,能够分化为多种类型的视网膜细胞。然而,获取用于个性化细胞治疗的诱导多能干细胞在时间和金钱方面成本高昂。由于诱导多能干细胞似乎是治疗视网膜疾病的一个现实选择,研究人员正在努力解决这一问题。脂肪来源间充质干细胞的优势在于获取过程较为简便。尽管干细胞应用取得了进展,但在将研究成果转化为临床应用之前,仍有几个挑战需要克服。本文综述了这三种类型干细胞应用的最新研究成果以及目前基于它们开展的临床试验。